Bio-Rad Laboratories (NYSE:BIO) today said it is launching is blood-based immunoassay kit to identify COVID-19 antibodies. The assay is currently undergoing clinical evaluation in several hospitals, but 700 samples of data have shown specificity above 99%. After being infected with SARS-CoV-2, viral antigens stimulate the immune system to produce antibodies and fight the virus. Bio-Rad suggests […]
Bio-Rad Laboratories
Patent board invalidates RainDance patent for obviousness
The Patent Trial and Appeal Board invalidated a RainDance Technologies patent earlier this week for obviousness. The patent, which covers a method for manipulating the size of liquid droplets used in microfluidic diagnostic tests, was challenged by manufacturer 10X Genomics Inc. The panel, after conducting an inter partes review, found that the technique’s characteristics, which […]
Bio-Rad Laboratories to acquire RainDance Technologies
Bio-Rad Laboratories (NYSE:BIO) said yesterday that it inked a definitive agreement to acquire RainDance Technologies for an undisclosed amount. The Hercules, Calif.-based company said it expects the transaction to close in the 1st quarter of 2017 and that it will reveal the terms of the acquisition when it discusses its 4th quarter and full-year financial […]
